Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 15/20 | 0.79 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.65 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | RARA | P10276 | 2/20 | 0.53 |
| ▸ | RARB | P10826 | 2/20 | 0.53 |
| ▸ | RARG | P13631 | 2/20 | 0.53 |
| ▸ | RXRA | P19793 | 2/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8421061 | 0.94 | PTGS2 (0.88) | PTGS2PTGS1AOC3CYP2C9RARA | |
| SCHEMBL4668470 | 0.93 | PTGS2 (0.69) | PTGS2PTGS1AOC3CYP2C9RARA | |
| SCHEMBL4907616 | 0.92 | PTGS2 (0.67) | PTGS2PTGS1AOC3CYP2C9RARA | |
| SCHEMBL8420266 | 0.88 | PTGS2 (0.79) | PTGS2PTGS1CYP2C9RARARARB | |
| SCHEMBL8423870 | 0.88 | PTGS2 (0.79) | PTGS2PTGS1AOC3 | |
| SCHEMBL8423953 | 0.88 | PTGS2 (0.79) | PTGS2PTGS1AOC3 | |
| SCHEMBL8420012 | 0.88 | PTGS2 (0.79) | PTGS2PTGS1CYP2C9RARARARB | |
| SCHEMBL8421124 | 0.83 | PTGS2 (0.89) | PTGS2PTGS1CYP2C9RARARARB | |
| SCHEMBL8420247 | 0.82 | CYP2C9 (0.71) | PTGS2PTGS1CYP2C9RARARARB | |
| SCHEMBL14280456 | 0.81 | ALOX5 (0.76) | PTGS2PTGS1AOC3CYP2C9ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030153569-A1 | Novel pyrazole and pyrazoline substituted compounds | SMITHKLINE BEECHAM CORPORATION | 2003-08-14 | — | — | US | claimed |
| US-20020156104-A1 | CSBP/p38/RK kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-10-24 | — | — | US | claimed |
| EP-1583535-A4 | METHODS FOR TREATING DIABETES | SCIOS INC (US) | 2008-03-19 | — | — | EP | disclosed |
| EP-1583535-A2 | METHODS FOR TREATING DIABETES | SCIOS INC. (US) | 2005-10-12 | — | — | EP | disclosed |
| US-20040171659-A1 | Methods for treating diabetes | SCIOS, INC. | 2004-09-02 | — | — | US | disclosed |
| US-6774127-B2 | TREATING CYTOKINE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION | 2004-08-10 | — | — | US | disclosed |
| WO-2004053107-A2 | METHODS FOR TREATING DIABETES | SCIOS INC. (US) | 2004-06-24 | — | — | WO | disclosed |
| US-20030153569-A1 | Novel pyrazole and pyrazoline substituted compounds | SMITHKLINE BEECHAM CORPORATION | 2003-08-14 | — | — | US | disclosed |
| US-20020156104-A1 | CSBP/p38/RK kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-10-24 | — | — | US | disclosed |
| EP-1023066-A4 | NOVEL PYRAZOLE AND PYRAZOLINE SUBSTITUTED COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2001-05-23 | — | — | EP | disclosed |
| EP-1023066-A1 | NOVEL PYRAZOLE AND PYRAZOLINE SUBSTITUTED COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-08-02 | — | — | EP | disclosed |
| WO-1998056377-A1 | NOVEL PYRAZOLE AND PYRAZOLINE SUBSTITUTED COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153569-A1 | Novel pyrazole and pyrazoline substituted compounds | PDXK, COQ8A, PDK3 | PTGS2 3455/4885PTGS1 3580/4885AOC3 2208/4885 |
| US-20040171659-A1 | Methods for treating diabetes | SLC5A2, MAPK4, MAPK3 | PTGS2 315/4885PTGS1 259/4885AOC3 2931/4885 |
| US-20020156104-A1 | CSBP/p38/RK kinase inhibitors | MAPKAPK2, MAPKAPK3, MAPKAPK5 | PTGS2 2606/4885PTGS1 2186/4885AOC3 4679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.